These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 12232752)

  • 1. Phase II study to evaluate combining gemcitabine with flutamide in advanced pancreatic cancer patients.
    Corrie P; Mayer A; Shaw J; D'Ath S; Blagden S; Blesing C; Price P; Warner N
    Br J Cancer; 2002 Sep; 87(7):716-9. PubMed ID: 12232752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers.
    Davis EJ; Griffith KA; Kim EJ; Ruch JM; McDonnell KJ; Zalupski MM
    Am J Clin Oncol; 2018 Feb; 41(2):128-132. PubMed ID: 26535993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.
    Bachet JB; Hammel P; Desramé J; Meurisse A; Chibaudel B; André T; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Meyer VG; Taieb J; Volet J; Monier A; Bonnetain F; Louvet C
    Lancet Gastroenterol Hepatol; 2017 May; 2(5):337-346. PubMed ID: 28397697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of gemcitabine and tamoxifen in advanced pancreatic cancer.
    Tomao S; Romiti A; Massidda B; Ionta MT; Farris A; Zullo A; Brescia A; Santuari L; Frati L
    Anticancer Res; 2002; 22(4):2361-4. PubMed ID: 12174927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
    Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma.
    Philip PA; Zalupski MM; Vaitkevicius VK; Arlauskas P; Chaplen R; Heilbrun LK; Adsay V; Weaver D; Shields AF
    Cancer; 2001 Aug; 92(3):569-77. PubMed ID: 11505401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I/II study of combination chemotherapy with gemcitabine and 5-fluorouracil for advanced pancreatic cancer.
    Okusaka T; Ishii H; Funakoshi A; Ueno H; Furuse J; Sumii T
    Jpn J Clin Oncol; 2006 Sep; 36(9):557-63. PubMed ID: 16870696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer.
    Oh DY; Cha Y; Choi IS; Yoon SY; Choi IK; Kim JH; Oh SC; Kim CD; Kim JS; Bang YJ; Kim YH
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):527-36. PubMed ID: 19578850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
    Starling N; Watkins D; Cunningham D; Thomas J; Webb J; Brown G; Thomas K; Oates J; Chau I
    J Clin Oncol; 2009 Nov; 27(33):5499-505. PubMed ID: 19858399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer.
    Bramhall SR; Schulz J; Nemunaitis J; Brown PD; Baillet M; Buckels JA
    Br J Cancer; 2002 Jul; 87(2):161-7. PubMed ID: 12107836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas.
    Feliu J; Mel R; Borrega P; López Gómez L; Escudero P; Dorta J; Castro J; Vázquez-Estévez SE; Bolaños M; Espinosa E; González Barón M;
    Ann Oncol; 2002 Nov; 13(11):1756-62. PubMed ID: 12419748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group.
    Xiros N; Papacostas P; Economopoulos T; Samelis G; Efstathiou E; Kastritis E; Kalofonos H; Onyenadum A; Skarlos D; Bamias A; Gogas H; Bafaloukos D; Samantas E; Kosmidis P
    Ann Oncol; 2005 May; 16(5):773-9. PubMed ID: 15802284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma.
    Scheithauer W; Kornek GV; Raderer M; Hejna M; Valencak J; Miholic J; Kovats E; Lang F; Funovics J; Bareck E; Depisch D
    Br J Cancer; 1999 Aug; 80(11):1797-802. PubMed ID: 10468299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study.
    Richards DA; Kuefler PR; Becerra C; Wilfong LS; Gersh RH; Boehm KA; Zhan F; Asmar L; Myrand SP; Hozak RR; Zhao L; Gill JF; Mullaney BP; Obasaju CK; Nicol SJ
    Invest New Drugs; 2011 Feb; 29(1):144-53. PubMed ID: 19714296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
    Ko AH; Truong TG; Kantoff E; Jones KA; Dito E; Ong A; Tempero MA
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):875-81. PubMed ID: 23053263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine plus irinotecan as first-line weekly therapy in locally advanced and/or metastatic pancreatic cancer.
    Neri B; Cipriani G; Grifoni R; Molinara E; Pantaleo P; Rangan S; Vannini A; Tonelli P; Valeri A; Pantalone D; Taddei A; Bechi P
    Oncol Res; 2009; 17(11-12):559-64. PubMed ID: 19806786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fixed dose rate infusion of gemcitabine with oral doxifluridine and leucovorin for advanced unresectable pancreatic cancer: a phase II study.
    Kim H; Park JH; Shin SJ; Kim MJ; Bang SJ; Park NH; Nah YW; Nam CW; Joo KR; Min YJ
    Chemotherapy; 2008; 54(1):54-62. PubMed ID: 18073472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
    Kozuch P; Grossbard ML; Barzdins A; Araneo M; Robin A; Frager D; Homel P; Marino J; DeGregorio P; Bruckner HW
    Oncologist; 2001; 6(6):488-95. PubMed ID: 11743211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weekly gemcitabine and 24-hour infusional 5-fluorouracil in advanced pancreatic cancer: a phase I-II study.
    Barone C; Cassano A; Corsi DC; Pozzo C; Longo R; Schinzari G; Quirino M; Battelli C; Basso M
    Oncology; 2003; 64(2):139-45. PubMed ID: 12566911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.